CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.
OBJECTIVE
To investigate the clinicopathologic characteristics of extracellular matrix (ECM) metalloproteinase inducer (CD147) and vascular endothelial growth factor (VEGF) expression in advanced renal cell carcinoma (RCC), and to evaluate the clinical significance of these two markers in the prognosis of advanced RCC.


METHODS
CD147 and VEGF expression in paraffin-embedded specimens gathered from 53 patients with advanced RCC and 12 healthy controls were detected by the method of immunohistochemistry. The Spearman correlation was calculated between the expression levels of CD147 and VEGF in advanced RCC tissues. The association of CD147 and VEGF expression with the clinicopathologic features and prognosis of advanced RCC was subsequently assessed.


RESULTS
CD147 and VEGF were positively expressed in 47/53 (88.7%) and 45/53 (84.9%) of patients with advanced RCC, respectively. Positive expression of CD147 (p= 0.02) and VEGF (p< 0.01) was significantly correlated with TNM stage of advanced RCC. A significant correlation was found between the expression of CD147 and VEGF in advanced RCC (r= 0.629, p= 0.04). Additionally, tumor CD147 and tumor VEGF expressions were significantly associated with the prognosis of advanced RCC patients. The survival rate of the patients with CD147-/VEGF- expression was the lowest (p< 0.01), and conjoined expressions of CD147-/VEGF- and CD147+/VEGF+ were independent prognostic indicators of advanced RCC (both p< 0.01).


CONCLUSIONS
The expression of CD147 or VEGF may be an important feature of advanced RCC. A combined detection of CD147/VEGF coexpression may benefit us in the prediction of the prognosis of advanced RCC.
Liang
Yu-Xiang
YX
Guangzhou First Municipal People's Hospital, Affiliated Guangzhou Medical College, Guangzhou, China.
He
Hui-Chan
HC
Han
Zhao-Dong
ZD
Bi
Xue-Cheng
XC
Dai
Qi-Shan
QS
Ye
Yong-Kang
YK
Qin
Wei-Jun
WJ
Zeng
Guo-Hua
GH
Zhu
Gang
G
Xu
Chuan-Liang
CL
Zhong
Wei-de
WD
D000368:Aged; D051926:Basigin / Q000032:analysis / Q000502:physiology*; D002292:Carcinoma, Renal Cell / Q000737:chemistry / Q000235:genetics* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000502:physiology*; D009367:Neoplasm Staging; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000502:physiology*
C497886:BSG protein, human; D009363:Neoplasm Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051926:Basigin